{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:59:45Z","timestamp":1786993185195,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jpba.2024.116020","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T04:13:32Z","timestamp":1707279212000},"page":"116020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Metabolic characterization of 25X-NBOH and 25X-NBOMe phenethylamines based on UHPLC-Q-Exactive Orbitrap MS in human liver microsomes"],"prefix":"10.1016","volume":"242","author":[{"given":"Jiahong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116020_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: a review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jpba.2024.116020_bib2","unstructured":"World Drug Report 2022: Booklet 4: Drug Market Trends of Cocaine, Amphetamine-Type Stimulants and New Psychoactive Substances. Available online: \u3008https:\/\/www.unodc.org\/res\/wdr2022\/MS\/WDR22_Booklet_4.pdf\u3009 (accessed on 5 April 2023)."},{"key":"10.1016\/j.jpba.2024.116020_bib3","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/ph16081158","article-title":"Unraveling the in vitro toxicity profile of psychedelic 2C phenethylamines and their N-benzylphenethylamine (NBOMe) analogues","volume":"16","author":"Martins","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jpba.2024.116020_bib4","article-title":"Severe 25E-NBOH intoxication associated with MDPHP intake: a case report, metabolism study, and literature review","author":"Pelletier","year":"2023","journal-title":"Int J. Leg. Med"},{"key":"10.1016\/j.jpba.2024.116020_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110884","article-title":"Simultaneous LC-MS\/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine","volume":"325","author":"Fan","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2024.116020_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2018.09.024","article-title":"Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT(2 A) receptors","volume":"158","author":"Eshleman","year":"2018","journal-title":"Biochem. Pharm."},{"issue":"23","key":"10.1016\/j.jpba.2024.116020_bib7","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1021\/acschemneuro.9b00528","article-title":"DARK classics in chemical neuroscience: NBOMes","volume":"11","author":"Poulie","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.jpba.2024.116020_bib8","first-page":"1","article-title":"Identification of thermolabile positional isomers of N-(2-hydroxybenzyl)-2-(dimethoxyphenyl) ethanamines (NBOH series) using chromatography and mass spectrometry methods","author":"Kupriyanova","year":"2024","journal-title":"Drug Test. Anal."},{"issue":"17","key":"10.1016\/j.jpba.2024.116020_bib9","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00216-023-04751-2","article-title":"Determination of synthetic hallucinogens in oral fluids by microextraction by packed sorbent and liquid chromatography-tandem mass spectrometry","volume":"415","author":"Lesne","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116020_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13181-013-0314-y","article-title":"2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing","volume":"10","author":"Stellpflug","year":"2014","journal-title":"J. Med. Toxicol."},{"issue":"8","key":"10.1016\/j.jpba.2024.116020_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1080\/15563650.2022.2053150","article-title":"A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)","volume":"60","author":"Ivory","year":"2022","journal-title":"Clin. Toxicol.."},{"key":"10.1016\/j.jpba.2024.116020_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.crtox.2021.11.002","article-title":"The new psychoactive substances 25H-NBOMe and 25H-NBOH induce abnormal development in the zebrafish embryo and interact in the DNA major groove","volume":"2","author":"de Barros","year":"2021","journal-title":"Curr. Res. Toxicol."},{"issue":"7","key":"10.1016\/j.jpba.2024.116020_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17720","article-title":"Neurotoxic effects of hallucinogenic drugs 25H-NBOMe and 25H-NBOH in organotypic hippocampal cultures","volume":"9","author":"Cassiano","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jpba.2024.116020_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/15563650.2015.1004179","article-title":"Prevalence of use and acute toxicity associated with the use of NBOMe drugs","volume":"53","author":"Wood","year":"2015","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.jpba.2024.116020_bib15","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16601","article-title":"The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism","volume":"11","author":"Zhou","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.jpba.2024.116020_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3609","article-title":"In vitro cannabinoid receptor activity, metabolism, and detection in seized samples of CH-PIATA, a new indole-3-acetamide synthetic cannabinoid","author":"Norman","year":"2023","journal-title":"Drug Test. Anal."},{"issue":"5","key":"10.1016\/j.jpba.2024.116020_bib17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/dta.2352","article-title":"Phase I metabolism of the recently emerged synthetic cannabinoid CUMYL-PEGACLONE and detection in human urine samples","volume":"10","author":"Mogler","year":"2018","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.jpba.2024.116020_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/metabo13030432","article-title":"Characterization of 3-hydroxyeticyclidine (3-HO-PCE) metabolism in human liver microsomes and biological samples using high-resolution mass spectrometry","volume":"13","author":"Larabi","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jpba.2024.116020_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110811","article-title":"Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19","volume":"387","author":"Hou","year":"2024","journal-title":"Chem. Biol. Inter."},{"issue":"10","key":"10.1016\/j.jpba.2024.116020_bib20","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/dta.2446","article-title":"In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models","volume":"10","author":"Grafinger","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2024.116020_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4939-8823-5_14","article-title":"Analysis of synthetic cannabinoid metabolites by liquid chromatography-tandem mass spectrometry","volume":"1872","author":"Janis","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.jpba.2024.116020_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/dta.2044","article-title":"25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry","volume":"9","author":"Wohlfarth","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"1","key":"10.1016\/j.jpba.2024.116020_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/acs.chemrestox.5b00450","article-title":"Metabolic fate of hallucinogenic NBOMes","volume":"29","author":"Leth-Petersen","year":"2016","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116020_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/molecules24040818","article-title":"In vitro metabolism of 25B-NBF, 2-(4-Bromo-2,5-Dimethoxyphenyl)-N-(2-Fluorobenzyl) ethanamine, in human hepatocytes using liquid chromatography(-)Mass spectrometry","volume":"24","author":"Kim","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jpba.2024.116020_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00414-018-1904-7","article-title":"Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry","volume":"133","author":"Seo","year":"2019","journal-title":"Int. J. Leg. Med"},{"key":"10.1016\/j.jpba.2024.116020_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jpba.2016.11.040","volume":"134","author":"Caspar","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.jpba.2024.116020_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/dta.2031","article-title":"Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH","volume":"9","author":"Nielsen","year":"2017","journal-title":"Drug Test. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2024.116020_bib28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jat\/bkx029","article-title":"Metabolic profile determination of NBOMe compounds using human liver microsomes and comparison with findings in authentic human blood and urine","volume":"41","author":"Temporal","year":"2017","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/j.jpba.2024.116020_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2006.03.001","article-title":"Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques","volume":"842","author":"Theobald","year":"2006","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"22","key":"10.1016\/j.jpba.2024.116020_bib30","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1007\/s00216-015-8828-6","article-title":"Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS(n), and LC-HR-MS\/MS","volume":"407","author":"Caspar","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2024.116020_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1556-4029.2012.02289.x","article-title":"Analysis of 4-bromo-2,5-dimethoxyphenethylamine abuser's urine: identification and quantitation of urinary metabolites","volume":"58","author":"Kanamori","year":"2013","journal-title":"J. Forensic Sci."},{"issue":"1","key":"10.1016\/j.jpba.2024.116020_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tox.2004.07.004","article-title":"Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human","volume":"206","author":"Carmo","year":"2005","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.jpba.2024.116020_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bcp.2006.09.022","article-title":"Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)","volume":"73","author":"Theobald","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116020_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0091-3057(82)90413-0","article-title":"Discriminative stimulus properties of DOM and several molecular modifications","volume":"16","author":"Glennon","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.jpba.2024.116020_bib35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0091-3057(03)00159-X","article-title":"Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM","volume":"75","author":"Eckler","year":"2003","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:41:30Z","timestamp":1715276490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"alternative-id":["S0731708524000608"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116020","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic characterization of 25X-NBOH and 25X-NBOMe phenethylamines based on UHPLC-Q-Exactive Orbitrap MS in human liver microsomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116020"}}